391 related articles for article (PubMed ID: 24571487)
1. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Chang YS
Respir Res; 2014 Feb; 15(1):26. PubMed ID: 24571487
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
3. mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells.
Le Bacquer O; Queniat G; Gmyr V; Kerr-Conte J; Lefebvre B; Pattou F
J Endocrinol; 2013 Jan; 216(1):21-9. PubMed ID: 23092880
[TBL] [Abstract][Full Text] [Related]
4. Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.
Misra UK; Pizzo SV
PLoS One; 2012; 7(12):e51735. PubMed ID: 23272152
[TBL] [Abstract][Full Text] [Related]
5. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
[TBL] [Abstract][Full Text] [Related]
6. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
[TBL] [Abstract][Full Text] [Related]
7. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.
Gulhati P; Bowen KA; Liu J; Stevens PD; Rychahou PG; Chen M; Lee EY; Weiss HL; O'Connor KL; Gao T; Evers BM
Cancer Res; 2011 May; 71(9):3246-56. PubMed ID: 21430067
[TBL] [Abstract][Full Text] [Related]
8. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
9. Aschantin targeting on the kinase domain of mammalian target of rapamycin suppresses epidermal growth factor-induced neoplastic cell transformation.
Lee CJ; Jang JH; Lee JY; Lee MH; Li Y; Ryu HW; Choi KI; Dong Z; Lee HS; Oh SR; Surh YJ; Cho YY
Carcinogenesis; 2015 Oct; 36(10):1223-34. PubMed ID: 26243309
[TBL] [Abstract][Full Text] [Related]
10. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
11. Nitidine chloride suppresses epithelial-to-mesenchymal transition in osteosarcoma cell migration and invasion through Akt/GSK-3β/Snail signaling pathway.
Cheng Z; Guo Y; Yang Y; Kan J; Dai S; Helian M; Li B; Xu J; Liu C
Oncol Rep; 2016 Aug; 36(2):1023-9. PubMed ID: 27279040
[TBL] [Abstract][Full Text] [Related]
12. Soluble epoxide hydrolase inhibition ameliorates proteinuria-induced epithelial-mesenchymal transition by regulating the PI3K-Akt-GSK-3β signaling pathway.
Liang Y; Jing Z; Deng H; Li Z; Zhuang Z; Wang S; Wang Y
Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):70-5. PubMed ID: 25986738
[TBL] [Abstract][Full Text] [Related]
13. TNF-α induces epithelial-mesenchymal transition of renal cell carcinoma cells via a GSK3β-dependent mechanism.
Ho MY; Tang SJ; Chuang MJ; Cha TL; Li JY; Sun GH; Sun KH
Mol Cancer Res; 2012 Aug; 10(8):1109-19. PubMed ID: 22707636
[TBL] [Abstract][Full Text] [Related]
14. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
15. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells.
Kim MR; Choi HK; Cho KB; Kim HS; Kang KW
Cancer Sci; 2009 Oct; 100(10):1834-41. PubMed ID: 19681904
[TBL] [Abstract][Full Text] [Related]
17. A critical role for the mTORC2 pathway in lung fibrosis.
Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
[TBL] [Abstract][Full Text] [Related]
18. mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer.
Chen X; Cheng H; Pan T; Liu Y; Su Y; Ren C; Huang D; Zha X; Liang C
Mol Carcinog; 2015 Oct; 54(10):1086-95. PubMed ID: 25043657
[TBL] [Abstract][Full Text] [Related]
19. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1.
Jin X; Yu Y; Zou Q; Wang M; Cui Y; Xie J; Wang Z
J Cell Biochem; 2019 Apr; 120(4):5880-5888. PubMed ID: 30317672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
